Neurocrine Biosciences' Ingrezza, Crenessity to Drive H2 Ahead of 'Catalyst-Rich' 2027, RBC Says

MT Newswires Live09-08 23:50

Neurocrine Biosciences' (NBIX) Ingrezza and Crenessity products are expected to drive H2 appreciation, ahead of a "catalyst-rich" 2027, RBC Capital Markets said in a Tuesday note.

Sales of both Ingrezza and Crenessity remain strong for the remainder of the year, while any improvement in Vykat's performance could provide upside, the brokerage said. Ingrezza is approved for the treatment of involuntary movement disorders, Crenessity for congenital adrenal hyperplasia and Vykat for hyperphagia.

A series of data readouts in 2027 serve as potential catalysts for Neurocrine Biosciences, including topline data from phase 3 studies of Osavampator in major depressive disorder, RBC said. Topline data from a phase 3 study of Direclidine in schizophrenia is also expected next year, the investment firm added.

Data from a phase 1 study of CRF2 agonist NBI-'2118 in obesity and a phase 2 study of VMAT2 inhibitor NBI-'890 in tardive dyskinesia are also slated for release in 2027, according to RBC.

RBC has an outperform rating and $198 price target on Neurocrine Biosciences.

Price: 156.05, Change: +0.41, Percent Change: +0.26

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2665379087?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-08 23:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2665379087","market":"sg","top_or_hot":-1,"title":"Neurocrine Biosciences' Ingrezza, Crenessity to Drive H2 Ahead of 'Catalyst-Rich' 2027, RBC Says","media":"MT Newswires Live","content":"<html><body><p> Neurocrine Biosciences' (NBIX) Ingrezza and Crenessity products are expected to drive H2 appreciation, ahead of a \"catalyst-rich\" 2027, RBC Capital Markets said in a Tuesday note.</p><p>Sales of both Ingrezza and Crenessity remain strong for the remainder of the year, while any improvement in Vykat's performance could provide upside, the brokerage said. Ingrezza is approved for the treatment of involuntary movement disorders, Crenessity for congenital adrenal hyperplasia and Vykat for hyperphagia.</p><p>A series of data readouts in 2027 serve as potential catalysts for Neurocrine Biosciences, including topline data from phase 3 studies of Osavampator in major depressive disorder, RBC said. Topline data from a phase 3 study of Direclidine in schizophrenia is also expected next year, the investment firm added.</p><p>Data from a phase 1 study of CRF2 agonist NBI-'2118 in obesity and a phase 2 study of VMAT2 inhibitor NBI-'890 in tardive dyskinesia are also slated for release in 2027, according to RBC.</p><p>RBC has an outperform rating and $198 price target on Neurocrine Biosciences.</p><p>Price: 156.05, Change: +0.41, Percent Change: +0.26</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neurocrine Biosciences' Ingrezza, Crenessity to Drive H2 Ahead of 'Catalyst-Rich' 2027, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeurocrine Biosciences' Ingrezza, Crenessity to Drive H2 Ahead of 'Catalyst-Rich' 2027, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-08 23:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Neurocrine Biosciences' (NBIX) Ingrezza and Crenessity products are expected to drive H2 appreciation, ahead of a \"catalyst-rich\" 2027, RBC Capital Markets said in a Tuesday note.</p><p>Sales of both Ingrezza and Crenessity remain strong for the remainder of the year, while any improvement in Vykat's performance could provide upside, the brokerage said. Ingrezza is approved for the treatment of involuntary movement disorders, Crenessity for congenital adrenal hyperplasia and Vykat for hyperphagia.</p><p>A series of data readouts in 2027 serve as potential catalysts for Neurocrine Biosciences, including topline data from phase 3 studies of Osavampator in major depressive disorder, RBC said. Topline data from a phase 3 study of Direclidine in schizophrenia is also expected next year, the investment firm added.</p><p>Data from a phase 1 study of CRF2 agonist NBI-'2118 in obesity and a phase 2 study of VMAT2 inhibitor NBI-'890 in tardive dyskinesia are also slated for release in 2027, according to RBC.</p><p>RBC has an outperform rating and $198 price target on Neurocrine Biosciences.</p><p>Price: 156.05, Change: +0.41, Percent Change: +0.26</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2665379087","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2665379087","pubTimestamp":1788882625,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Neurocrine Biosciences'  Ingrezza and Crenessity products are expected to drive H2 appreciation, ahead of a \"catalyst-rich\" 2027, RBC Capital Markets said in a Tuesday note.Sales of both Ingrezza and Crenessity remain strong for the remainder of the year, while any improvement in Vykat's performance could provide upside, the brokerage said. Ingrezza is approved for the treatment of involuntary movement disorders, Crenessity for congenital adrenal hyperplasia and Vykat for hyperphagia.A series of data readouts in 2027 serve as potential catalysts for Neurocrine Biosciences, including topline data from phase 3 studies of Osavampator in major depressive disorder, RBC said. Topline data from a phase 3 study of Direclidine in schizophrenia is also expected next year, the investment firm added.Data from a phase 1 study of CRF2 agonist NBI-'2118 in obesity and a phase 2 study of VMAT2 inhibitor NBI-'890 in tardive dyskinesia are also slated for release in 2027, according to RBC.RBC has an out","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU0154245756.USD":"BNP PARIBAS US MID CAP \"C\" (USD) ACC","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","NBIX":"神经分泌生物科学","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0154245673.USD":"BNP PARIBAS US MID CAP \"C\" (USD) INC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC"},"translate_title":"加拿大皇家银行表示，Neurocrine Biosciences 的 Ingrezza 和 Crenessity 将在“富含催化剂”的 2027 年之前推动 H2","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NBIX":1.5},"content_text":"Neurocrine Biosciences' (NBIX) Ingrezza and Crenessity products are expected to drive H2 appreciation, ahead of a \"catalyst-rich\" 2027, RBC Capital Markets said in a Tuesday note.Sales of both Ingrezza and Crenessity remain strong for the remainder of the year, while any improvement in Vykat's performance could provide upside, the brokerage said. Ingrezza is approved for the treatment of involuntary movement disorders, Crenessity for congenital adrenal hyperplasia and Vykat for hyperphagia.A series of data readouts in 2027 serve as potential catalysts for Neurocrine Biosciences, including topline data from phase 3 studies of Osavampator in major depressive disorder, RBC said. Topline data from a phase 3 study of Direclidine in schizophrenia is also expected next year, the investment firm added.Data from a phase 1 study of CRF2 agonist NBI-'2118 in obesity and a phase 2 study of VMAT2 inhibitor NBI-'890 in tardive dyskinesia are also slated for release in 2027, according to RBC.RBC has an outperform rating and $198 price target on Neurocrine Biosciences.Price: 156.05, Change: +0.41, Percent Change: +0.26","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2665379087","isCrawlerRequest":true}